Side Effects: Variety Is Overrated

• by Kerri Miller

• March 30, 2026

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

• by Kathryn Wighton

• July 16, 2026

• 2 min

Could Pregnancy Complications Predict CVD Risk?

Investigators found that adding pregnancy-related and female-specific factors modestly improved postpartum cardiovascular risk prediction compared with traditional risk factors alone.

• by Andrea Surnit

• August 5, 2026

• 4 min

FDA Approves At-Home Starting Dose for Lecanemab

Patients may begin lecanemab-irmb treatment at home through self-administration or administration by a caregiver, according to the FDA.

• by Kathryn Wighton

• July 13, 2026

• 3 min